Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 11/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5744663 | 0.89 | DPP4 (0.65) | DPP4MAPTKDM4ESMN1; SMN2LMNA | |
| SCHEMBL5744977 | 0.89 | DPP4 (0.70) | DPP4MAPTKDM4ESMN1; SMN2LMNA | |
| SCHEMBL5743886 | 0.87 | DPP4 (0.59) | DPP4 | |
| SCHEMBL11003403 | 0.86 | DPP4 (0.70) | DPP4MAPTKDM4ESMN1; SMN2LMNA | |
| SCHEMBL5743621 | 0.85 | DPP4 (0.60) | DPP4MAPTKDM4ESMN1; SMN2LMNA | |
| SCHEMBL5744910 | 0.85 | DPP4 (0.60) | DPP4KDM4ESMN1; SMN2HTT | |
| SCHEMBL5745407 | 0.84 | DPP4 (0.58) | DPP4MAPTKDM4ESMN1; SMN2LMNA | |
| SCHEMBL5767998 | 0.83 | DPP4 (0.57) | DPP4MAPTKDM4ESMN1; SMN2LMNA | |
| SCHEMBL5743641 | 0.81 | DPP4 (0.66) | DPP4MAPTLMNATP53 | |
| SCHEMBL5745206 | 0.80 | DPP4 (0.55) | DPP4MAPTKDM4ESMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7067529-B2 | Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2006-06-27 | — | — | US | disclosed |
| EP-1631551-A2 | ISOQUINOLINE DERIVATIVES AND THEIR USE AS GFAT INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-08 | — | — | EP | disclosed |
| US-20040259910-A1 | Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors | BOLIN DAVID ROBERT (US) | 2004-12-23 | — | — | US | disclosed |
| WO-2004101528-A2 | ISOQUINOLINE DERIVATIVES AND THEIR USE AS GFAT INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259910-A1 | Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors | GFPT1, GLS2, GLS | DPP4 134/4885MAPT 1626/4885KDM4E 1245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.